Abstract: A device for supporting the human foot is provided. The device includes: a first layer comprising an arch at a central region; a second layer coupled to the first layer at a first end at a heel region and at a second end at a forefoot region; and a rigid deflection element disposed between the first and second ends and at least partially between the first and second layers, a spacing between the first and second layers at the location of the deflection element is defined by the deflection element; the first and second layers have a first spacing between the first end and the deflection element and have a second spacing between the deflection element and the second end, the arch is based on the first spacing, and the first spacing is configured to increase from a first height to a second height when the second spacing decreases.

Abstract: A device for supporting the human foot may include a first layer forming an arch in a central region of the device and a second layer that is connected to the first layer in a first end region and in a second end region of the device. The device may include at least one deflection element with dorsiflexion of the device. The second layer may be designed to transmit tension acting in the second end region via the deflection element to the first layer in the second end region in such a way that the dorsiflexion leads to an increase in the height of the arch formed by the first layer. The deflection element may be arranged at least partially between the first layer and the second layer, such that the first layer and second layer are spaced apart at a distance specified by the deflection element(s).

Abstract: A device for supporting the human foot may include a first layer forming an arch in a central region of the device and a second layer that is connected to the first layer in a first end region and in a second end region of the device. The device may include at least one deflection element with dorsiflexion of the device. The second layer may be designed to transmit tension acting in the second end region via the deflection element to the first layer in the second end region in such a way that the dorsiflexion leads to an increase in the height of the arch formed by the first layer. The deflection element may be arranged at least partially between the first layer and the second layer, such that the first layer and second layer are spaced apart at a distance specified by the deflection element(s).

Abstract: The present invention describes a test system for the determination of in-vivo active hemostasis proteases in biological fluids and the use thereof to determine the in-vivo activation of hemostasis or to diagnose pancreatitis.

Abstract: Described is an anti-Limulus-factors-independent procedure to measure the lipopolysaccharide (LPS)- and/or lipid-A and/or glucan-reactivity in biologic liquids with the aid of a modified Limulus-test. Anti-Limulus-factors-independence is obtained by strongly-oxidative treatment of the sample.

Abstract: A description is given of the possibility of using transglutaminases in a process for the preparation of an immunosuppressant. Additionally described is a pharmaceutical containing a transglutaminase and a plasminogen activator inhibitor.

Abstract: The disclosed invention provides a method for determining the plasminogen activator (PA) activity in a biological fluid. The method involves the use of proteolytically-degraded plasminogen and effectively eliminates the influence of alpha-2-antiplasmin on the determination of PA activity.

Abstract: A method and an agent for the functional determination of protein C inhibitor in body fluids are described, in which this fluid is incubated with a known amount of a plasminogen activator, fibrinogen and a sulfated carbohydrate, and the residual activity of the plasminogen activator is determined, and from this the amount of protein C inhibitor is determined.

Abstract: A description is given of the possibility of using transglutaminases in a process for the preparation of an immunosuppressant.Additionally described is a pharmaceutical containing a transglutaminase and a plasminogen activator inhibitor.

Abstract: Oxidized derivatives of-fibrin and fibrin or fibrinogen degradation products or partial sequences, process for their preparation and their use as medicaments, for diagnosis or as an affinity agent are described.

Abstract: Oxidized derivatives of fibrin and fibrin or fibrinogen degradation products or partial sequences, process for their preparation and their use as medicaments, for diagnosis or as an affinity agent are described.

Abstract: The invention relates to a method for the determination of the activity of serine proteases and serine protease inhibitors in plasma or other biological fluids.The only methods hitherto available for rapid and accurate determination of the content of serine proteases or serine protease inhibitors have been very time-consuming and methodologically demanding. In the method according to the invention for the determination of the activity of serine proteases or serine protease inhibitors, specific inhibitors are inactivated by addition of at least one oxidizing agent and, where appropriate, at least one detergent. The addition of an omega-aminocarboxylic acid enhances and observed effects when the serine protease is plasmin.